AstraZeneca to buy Amolyt Pharma for $1.05 Billion to Boost Rare-Disease Portfolio

AstraZeneca to buy Amolyt Pharma for $1.05 Billion to Boost Rare-Disease Portfolio

Drugmaker AstraZeneca announced on Thursday its intention to acquire Amolyt Pharma, a company specializing in endocrine diseases, for a hefty…

Read More »